Latest Information Update: 16 Mar 2007
At a glance
- Originator Roche
- Class Obesity therapies
- Mechanism of Action Melanocortin type 4 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 16 Mar 2007 Discontinued - Preclinical for Obesity in USA (unspecified route)
- 12 Jun 2001 No-Development-Reported for Obesity in USA (Unknown route)
- 17 Dec 1998 New profile